In both trials, envudeucitinib showed greater skin clearance than placebo on both co-primary endpoints at week 16.

Congress is considering legislation that would address misaligned prescription drug cost incentives set by pharmacy benefit managers, or PBMs. I applaud Congress for acting on this pressing issue, ...

Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...

Insurers' use of step therapy for specialty drugs varies widely, according to a new study. The analysis, led by researchers at Tufts University and published in Health Affairs, tracked the application ...

September 19, 2025 - Alexandria, VA - The National Psoriasis Foundation (NPF), the leading nonprofit dedicated to curing psoriatic disease and improving the lives of those affected, applauds ...

Biologics have changed the game when it comes to psoriasis treatment. Your doctor might suggest them if you have a serious disease. That means you’ve got plaques on more than 5% to 10% of your body.

A real world systematic review and meta-analysis found tildrakizumab improved plaque psoriasis severity and quality of life ...